After finishing my chemistry studies at the university of Göttingen (Germany) with a diploma-thesis investigating structural aspects of a myleoma immunoglobulin A applying mass spectrometric methods, I started my professional career at Biochemie GesmbH in Kundl (Austria), today known as Sandoz.
At Biochemie, I initially worked as an Interim Laboratory Head in the R&D department before changing into the department Biotech Production to become Plant Manager Assistant. In the beginning, I was responsible for Biochemie's contract manufacturing services for third parties in a multi purpose plant. I was able to achieve additional experience in contract manufacturing and project management when I was asked to oversee contract manufacturing of Biochemie's first biosimilar product during an on-site stay at a U.S.-based contract manufacturing organisation. After successful completion of the manufacturing campaign in the U.S., I was responsible for transfer back to and validation of the manufacturing process at Biochemie.
In the following, I joined STADA Arzneimittel AG in Bad Vilbel (Germany) to support their biosimilar venture Bioceuticals Arzneimittel AG. Starting as Project Coordinator and finally becoming Head of Projectmanagement Biotechnology, I was responsible for the technical and scientific project management of a successful Epoetin biosimilar development program and four biosimilar monoclonal antibody projects. Based on the concept to assign the development work nearly entirely to third party service providers, I was able to work actively and hands-on in the projects allowing me to gain deep insight into the entire development process starting from cell line selection and manufacturing process development through dossier preparation and marketing authorisation application up to commercial launch and market supply.
Leaving STADA Arzneimittel AG after more than 10 years, I joined AET BioTechnologie GmbH in Hamburg (Germany) to become Head of Project Management helping to build-up the company and develop a biosimilar adalimumab.
Since November 2016, I am working as a freelancer offering my experience and knowledge to companies in the biosimilar space.